Expertise in
16
conditions

Dr. Peter M. Voorhees

The Charlotte-Mecklenburg Hospital Authority
Charlotte, NC
Expertise in
16
conditions
Specialties:Hematology | Hematology Oncology
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
OverviewInsuranceLocationsClinical Research

Overview

Peter Voorhees is a Hematologist and a Hematologist Oncology provider in Charlotte, North Carolina. Dr. Voorhees is highly rated in 16 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Voorhees is currently accepting new patients.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Carolinas Medical Center-Northeast
Carolinas Medical Center/behav Health
Atrium Health University City
North Carolina Baptist Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  UnitedHealthcare

Locations

THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
1021 Morehead Medical Dr, Suite A, Charlotte, NC 28204
980-442-2000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 23, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

117 Total Publications

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Journal: The New England journal of medicine
Published: December 09, 2024
Similar Doctors
Expertise in
18
conditions
Dr. Ruben A. Mesa
Hematology | Hematology Oncology | Oncology
Expertise in
18
conditions
Dr. Ruben A. Mesa
Hematology | Hematology Oncology | Oncology

The Charlotte-Mecklenburg Hospital Authority

1021 Morehead Medical Dr, Suite A, 
Charlotte, NC 
980-442-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and a Hematologist Oncology provider in Charlotte, North Carolina. Dr. Mesa is highly rated in 18 conditions, according to our data. His top areas of expertise are Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Bone Marrow Transplant, and Splenectomy. Dr. Mesa is currently accepting new patients.

Expertise in
11
conditions
Dr. Payal C. Desai
Hematology | Hematology Oncology
Expertise in
11
conditions
Dr. Payal C. Desai
Hematology | Hematology Oncology

The Charlotte-Mecklenburg Hospital Authority

1021 Morehead Medical Dr, Suite A, 
Charlotte, NC 
980-442-2000
Languages Spoken:
English, Sign Language
See accepted insurances
Accepting New Patients

Payal Desai is a Hematologist and a Hematologist Oncology provider in Charlotte, North Carolina. Dr. Desai is highly rated in 11 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Desai is currently accepting new patients.

Expertise in
12
conditions
Dr. Manisha Bhutani
Hematology | Hematology Oncology | Oncology
Expertise in
12
conditions
Dr. Manisha Bhutani
Hematology | Hematology Oncology | Oncology

The Charlotte-Mecklenburg Hospital Authority

1021 Morehead Medical Dr, Suite A, 
Charlotte, NC 
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manisha Bhutani is a Hematologist and a Hematologist Oncology provider in Charlotte, North Carolina. Dr. Bhutani is highly rated in 12 conditions, according to our data. Her top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhutani is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile